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Objective: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc). In 
this longitudinal study, we aimed to identify factors associated with an unfavourable outcome in SSc 
patients with early PAH (SSc-PAH) from the DETECT cohort. 
Methods: Patients with SSc-PAH enrolled in DETECT were observed for up to 3 years. Associations 
between cross-sectional variables and disease progression (defined as the occurrence of any of the following 
events: World Health Organization Functional Class worsening, combination therapy for PAH, 
hospitalisation, or death) were analysed by univariable logistic regression.  
Results: Of 57 patients with PAH (median observation time 12.6 months), 25 (43.9%) had disease 
progression. The following factors [odds ratio, (95% confidence interval)] were associated with disease 
progression: male gender [4.1 (1.2-14.1)], high Forced Vital Capacity (FVC) % predicted/ DLCO % 
predicted ratio [3.6 (1.2-10.7)], high Borg dyspnoea index [1.7 (1.1-2.6)], and DLCO % predicted (non-
linear relationship).  
Conclusion: More than 40% of early-diagnosed SSc-PAH patients had disease progression during a short 
follow-up time, with male gender, functional capacity, and pulmonary function tests at PAH diagnosis being 
associated with progression. This suggests that even mild PAH should be considered a high-risk 
complication of SSc. 
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INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), with high 
mortality if not promptly diagnosed and treated.[1,2] Correct diagnosis of PAH requires invasive 
investigation by right-sided heart catheterisation (RHC).[3] 
The DETECT study was the first multicentre, real-life study systematically using RHC in patients with SSc 
at increased risk to develop PAH.[4] In its cross-sectional stage, DETECT developed an algorithm able to 
select patients with SSc and a high suspicion of PAH for referral to RHC, minimizing missed diagnoses in 
addition to identifying patients with milder PAH, in whom prompt  
institution of treatment might improve the disease course.   
However, the prognosis of these patients with early detection of PAH has not been established to date. As 
part of the DETECT study, patients have been observed longitudinally for up to 3 years. This study reports 
on the longitudinal phase of the DETECT study, aiming to describe factors associated with an unfavourable 
outcome in patients with an early diagnosis of SSc-PAH. 
 
PATIENTS AND METHODS 
Data collection during the longitudinal stage of DETECT 
The cross-sectional part of the DETECT study has been published.[4] Eighteen of the 62 centres involved 
in DETECT continued to follow up patients diagnosed with SSc-PAH at baseline on a yearly basis. The 
following data were recorded: survival status, reason for end of follow-up or death, WHO Functional Class 
(FC), PAH-related hospitalization (>1 day) since last visit, 6-Minute walk distance (6MWD), current or 
past treatment with PAH specific therapies, including duration of therapy, and combination therapy. At the 
time of longitudinal data collection, combination therapy for PAH was used for more severe PAH, as the 
advantages of upfront combination therapy for PAH have emerged later.[5] Patients in WHO-FC I and II 




Disease progression was defined by expert consensus as a composite outcome, based on the presence of at 
least one of the following events during follow-up: worsening in WHO FC from enrolment; presence of 
combination therapy for PAH; PAH-related hospitalization; and death from any cause.  
The main analysis set comprises all SSc-PAH patients who were included in the longitudinal stage of the 
DETECT study and who had available follow-up data. The complementary set of SSc-PAH patients, who 
could not be included in the longitudinal stage, was used only for examining any potential selection bias 
that may have occurred. Two subgroups of the SSc-PAH analysis set were defined by the binary disease 
progression outcome i.e., “With disease progression” (progressive PAH) or “Without disease progression” 
(stable PAH).  
Twenty-one of 121 baseline (cross-sectional) variables considered to be potential predictors of disease 
progression were selected for further analysis, based on input from the authors on feasibility of the variables 
and on their clinical relevance to PAH. Univariable Logistic Regression (ULR) analysis was performed 
using the binary disease progression outcome as dependent variable and the selected baseline variables as 
independent variables. ULR included the determination of odds ratio (OR) and its 95% confidence interval 
(95% CI), and area under the receiver-operating characteristic curve (ROC-AUC) and its 95% CI. Accuracy 
of a predictor was considered fair if its AUC was <0.70. For each continuous baseline variable analysed by 
ULR, a quadratic term in the regression model was also included, in order to examine a non-linear 
functional relationship with the outcome. A sensitivity analysis, excluding patients with missing outcome 
data, was also performed. The statistical analysis plan was developed and analyses were carried out by 
qualified statisticians using the SAS software (version 9.4.).  
 
RESULTS 
Study cohort  
Of the 145 patients with SSc-PH identified in the DETECT study, 87 (60%) had PAH, of whom 57 patients 
had follow-up visits and the remaining 30 patients did not have follow-up visits (Figure 1). Median time of 
follow-up was 12.6 months (range 2.4-35.8, interquartile range 10.7-21.7).  
 
Demographic and clinical characteristics 
Using the composite definition of disease progression, 25/57 (43.9%) of the PAH patients with longitudinal 
data had progressive PAH and 32/57 (56.1%) had stable PAH. Demographics and clinical characteristics at 
enrolment of all, stable and progressive PAH patients respectively are displayed in Table 1. Baseline mean 
mPAP was 32.5 (standard deviation 8.3) mmHg and 33/57 (57.9%) of patients were in WHO-FC I or II. 
Stable PAH patients had a slightly longer follow-up, when compared to progressive PAH patients ([months, 
mean, (Q1, Q3)]: 13.0 (11.0, 21.6) vs. 11.7 (10.2, 21.9)) but this difference was not significant (as shown 
by the overlapping 95% Hall-Wellner Bands of the Kaplan-Meier estimates, Figure S1 in the online 
supplement). Twenty-four of the 25 patients with progressive PAH and 28/32 patients with stable PAH 
received PAH treatment during follow-up. Four patients had missing data among the outcomes defining 
disease progression; they were included in the subgroup without disease progression (see Table 1), but were 
excluded in the sensitivity analysis. 
 
Disease progression events  
Among the 25 patients with disease progression, 4 died, 11 were hospitalized for PAH, 14 had at least one 
occurrence of worsening in WHO-FC, and 8 received PAH-specific combination treatment. Among the 4 
patients who died, 3 were died from a PAH-related cause (all in WHO-FC III at enrolment), while the fourth 
died from severe pneumonia complicating surgery on the leg. Time to death in all cases was <12 months 
from baseline (range 2.4 - 10.5 months). Although the 1-year survival rate in this cohort was high (93%), 
there is some uncertainty as shown by the wide 95% Hall-Wellner Bands (online supplement, Figure S1). 
Table 1. Description of demographic and clinical characteristics at enrolment (cross-sectional stage) by 
group 
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* from the first non-Raynaud symptom 
 
Q1,Q3 = interquartile range; dcSSc – diffuse cutaneous SSc;  WHO – World Health Organization; DLCO – carbon monoxide lung 
diffusion capacity; FVC – forced vital capacity; ACA – anti-centromere antibodies; NT-proBNP – N-terminal pro-(Brain 
Natriuretic Peptide); ECG – electrocardiogram; TR – tricuspid regurgitation; RHC – right-sided heart catheterization; mPAP – 
mean pulmonary artery pressure on RHC; PCPW – pulmonary capillary wedge pressure; PVR – pulmonary vascular resistance.    
  
 
 Factors associated with disease progression  
Baseline factors potentially associated with PAH disease progressionwere analysed by ULR (table 2). Male 
gender, high FVC%/DLCO%, low DLCO%, and high Borg dyspnoea index at enrolment were found to be 
significantly associated with disease progression. However, the first two had an AUC<0.70, denoting a 
relatively poor performance as single predictors. The results of the sensitivity analysis were similar and are 
reported in the online supplement. 















(N = 32) 
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Demographics      
Age 25 32 0.985 (0.929-1.045) 0.623 0.539 (0.38- 0.695) 
Male sex 25 31 4.085 (1.181-14.128) 0.026 0.639 (0.520-0.758) 
Disease 
characteristics 
     
Disease duration 
(months) 
25 32 0.999 (0.994-1.003) 0.548 0.514 (0.357-0.672) 
SSc subtype (dcSSc 
vs. lcSSc) 
25 32 0.978 (0.288-3.325) 0.971 0.566 (0.436-0.697) 
Functional capacity      
WHO functional class      
I+II vs. III+IV 25 32 0.650 (0.225-1.880) 0.427 0.553 (0.421-0.684) 
6-min walk test 20 24 0.996 (0.990-1.001) 0.141 0.621 (0.450-0.791) 
Borg dyspnoea index 21 24 1.685 (1.092-2.598) 0.018 0.711 (0.560-0.863) 
Pulmonary function tests     
DLCO % 25 32 -§ 0.008 0.753 (0.626-0.881) 
FVC%/DLCO% 25 32 3.608 (1.223-10.647) 0.020 0.693 (0.553-0.832) 
Laboratory tests      
ACA positive 25 30 0.688 (0.237-1.998) 0.491 0.547 (0.412-0.681) 
NT-proBNP 25 30 1.668 (0.595-4.673) 0.330 0.599 (0.446-0.753) 
 § The odds ratio is not given, because the quadratic functional relationship in the ULR model showed statistical significance. The 
p-value and ROC-AUC are from the ULR model with the quadratic functional form. A sensitivity analysis excluding 4 patients 
with missing data on disease progression did not change the conclusions. 
 
Disease progression was defined as presence of one of the following events: clinical worsening, combination PAH therapy, 
hospitalization, or death. All variables except gender, disease subset and ACA-positivity have been analysed as linear terms. Results 
in bold characters are statistically significant. 
OR – odds ratio; 95% CI – 95% confidence interval; AUC – area under the curve; dcSSc – diffuse cutaneous SSc;  lcSSc – limited 
cutaneous SSc; ACA – anti-centromere antibodies; WHO – World Health Organization; DLCO – carbon monoxide lung diffusion 
capacity; FVC – forced vital capacity; NT-proBNP – N-terminal pro-(Brain Natriuretic Peptide); ECG – electrocardiogram; US – 
ultrasonography; TR – tricuspid regurgitation; RHC – right-sided heart catheterization; mPAP – mean pulmonary artery pressure 
on RHC; PCPW – pulmonary capillary wedge pressure; PVR – pulmonary vascular resistance.    
Serum uric acid 25 30 1.224 (0.853-1.756) 0.272 0.601 (0.448-0.755) 
ECG parameters      
Right axis deviation 25 30 0.952 (0.226-4.008) 0.947 0.503 (0.403-0.603) 
Right ventricular 
strain 
25 30 0.952 (0.226-4.008) 0.947 0.503 (0.403-0.603) 
Echocardiography parameters     
US right atrium area 22 31    1.019 (0.923-1.126) 0.704 0.609 (0.456-0.761) 
US right ventricle 
area 
21 32    1.034 (0.952-1.124) 0.424 0.601 (0.448-0.755) 
TR velocity 22 29    1.204 (0.503-2.881) 0.677 0.522 (0.355-0.689) 
RHC parameters      
Cardiac index 25 31 1.129 (0.492- 2.586) 0.775 0.492 (0.333-0.650) 
mPAP 25 32 1.018 (0.951-1.090) 0.607 0.561 (0.411-0.712) 
Mean PCWP 25 32 0.864 (0.720-1.037) 0.117 0.616 (0.463-0.768) 




This study is the first longitudinal observation of a cohort of patients with SSc-PAH diagnosed by 
systematic RHC.[4] Most patients had mild or no PAH symptoms. None of these patients had been 
diagnosed with PH by RHC before study enrolment and the majority were in WHO FC I and II (33/57, 
57.9%).  
We observed that 25/57 patients (43.9%) had disease progression during a median follow-up of 12.6 
months; 13/25 were in WHO-FC I or II and 4/25 died during the first 12 months since PAH diagnosis (1-
year survival rate 93%). This demonstrates that even mild PAH should be regarded as a high-risk 
complication of SSc.  
The factors found to be associated with disease progression were male gender, lower DLCO%, higher 
FVC%/DLCO% ratio, and higher Borg dyspnoea index. These factors are similar to risk factors identified 
for more advanced PAH patients.[7-11]  Low DLCO and male gender are independent, major risk factors 
for death in all SSc patients, as shown in several large cohorts.[12-14] Higher FVC%/DLCO% ratio is not 
only a risk factor for PAH in patients with SSc [4], but also suggests the absence of significant interstitial 
lung disease. Of note, patients in the DETECT cohort had, by enrolment criteria, DLCO<60% predicted 
and FVC>40% predicted; this has certainly influenced the FVC%/DLCO% ratio, which was rather high in 
the entire DETECT cohort.  
The risk factors identified by our exploratory analysis are highly feasible to use in clinical practice. 
Particular attention should be given to DLCO monitoring, both for PAH screening and prognostic purposes 
in patients with SSc.  
One of the main strengths of this study is the uniqueness of the DETECT cohort, in which every patient 
underwent RHC at enrolment and had not been diagnosed with PAH before. High data quality was ensured 
by standardised echocardiographic and RHC protocols in all centres, with centralised laboratory testing and 
data management, and strict data quality monitoring.[4] The composite definition of disease worsening 
includes strong outcomes like death and hospitalization due to PAH, adjudicated as per investigators’ 
judgement.  
One of the study limitations is the lack of longitudinal data in 30 patients with SSc-PAH from the original 
DETECT cohort. However, the baseline data displayed in Table 1 show that these patients without follow-
up data were in most aspects similar to PAH patients having longitudinal data. Another potential limitation 
is the preselected nature of this cohort, limiting generalisation of our results. Although 4 patients in the 
PAH cohort had missing data on disease progression and were classified as having stable PAH, obtaining 
similar results in the sensitivity analysis which excluded these patients proved the validity of our results. 
Further potential limitations include the relatively short follow-up, the variability in PAH treatment due to 
the international, multicentre character of the study and the impossibility to perform multivariable analysis 
or to adjust the analysis for PAH treatment, due to the small number of cases. 
In conclusion, the results of our study have practical implications, as they show that patients with early 
SSc-PAH have a meaningful rate of disease progression over a relatively short time, requiring close follow-
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